-
Je něco špatně v tomto záznamu ?
Predictors of Secukinumab Treatment Response and Continuation in Axial Spondyloarthritis: Results From the EuroSpA Research Collaboration Network
M. Pons, S. Georgiadis, ML. Hetland, ZF. Ahmadzay, S. Rasmussen, SN. Christiansen, D. Di Giuseppe, JK. Wallman, K. Pavelka, J. Závada, C. Codreanu, B. Glintborg, AG. Loft, H. Santos, MH. Lourenço, MJ. Nissen, A. Ciurea, L. Kuusalo, V. Rantalaiho,...
Journal of rheumatology.
2025 ;
52 (6) :
572-582.
[pub] 20250601
Jazyk angličtina Země Kanada
Typ dokumentu časopisecké články
Perzistentní odkaz
https://www.medvik.cz/link/bmc25015563
PubMed
39892891
DOI
10.3899/jrheum.2024-0920
Knihovny.cz E-zdroje
- MeSH
- antirevmatika * terapeutické užití MeSH
- axiální spondyloartritida * farmakoterapie MeSH
- C-reaktivní protein metabolismus MeSH
- dospělí MeSH
- humanizované monoklonální protilátky * terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- registrace MeSH
- stupeň závažnosti nemoci MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Evropa MeSH
OBJECTIVE: In patients with axial spondyloarthritis (axSpA) initiating secukinumab (SEC), we aimed to identify baseline (treatment start) predictors of achieving low disease activity (LDA) after 6 months, as measured by the Axial Spondyloarthritis Disease Activity Score using C-reactive protein (ASDAS-CRP) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), as well as treatment continuation after 12 months. METHODS: From 11 European registries, patients with axSpA who initiated SEC treatment in routine care, with available data on 6-month ASDAS-CRP and BASDAI assessments were included. Logistic regression analyses on multiply imputed baseline data were performed; potential baseline predictors included demographic, diagnosis, lifestyle, clinical, and patient-reported variables. RESULTS: In a pooled cohort of 1174 patients with axSpA, 5 of 19 potential assessed variables were mutually predictive for achieving LDA by ASDAS-CRP and BASDAI: higher physician global assessment score, noncurrent smoking, lack of prior exposure to biologic/targeted synthetic disease-modifying antirheumatic drugs, and lower Health Assessment Questionnaire scores and BASDAI scores. Moreover, radiographic axSpA and CRP ≤ 10 mg/L were associated with achieving ASDAS-CRP LDA, and HLA-B27 positivity and history of psoriasis with achieving BASDAI LDA, whereas earlier time of secukinumab initiation (2015-2017) was associated with treatment continuation. CONCLUSION: In this European real-world study of patients with axSpA initiating SEC, predictors of achieving LDA by ASDAS-CRP and BASDAI at 6 months and remaining on treatment at 12 months included both clinical, patient-reported, and lifestyle factors, underscoring the complex mechanisms of real-world drug effectiveness.
C Codreanu PhD Center for Rheumatic Diseases University of Medicine and Pharmacy Bucharest Romania
K Laas PhD Department of Rheumatology East Tallinn Central Hospital Tallinn Estonia
M J Nissen MD PhD Department of Rheumatology Geneva University Hospital Geneva Switzerland
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25015563
- 003
- CZ-PrNML
- 005
- 20250731091058.0
- 007
- ta
- 008
- 250708s2025 xxc f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3899/jrheum.2024-0920 $2 doi
- 035 __
- $a (PubMed)39892891
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxc
- 100 1_
- $a Pons, Marion $u M. Pons, MD, S. Georgiadis, PhD, S. Rasmussen, PhD, S.N. Christiansen, PhD, L.M. Ørnbjerg, MD, PhD, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark; marion.pons.senlis@gmail.com $1 https://orcid.org/0000000165319846
- 245 10
- $a Predictors of Secukinumab Treatment Response and Continuation in Axial Spondyloarthritis: Results From the EuroSpA Research Collaboration Network / $c M. Pons, S. Georgiadis, ML. Hetland, ZF. Ahmadzay, S. Rasmussen, SN. Christiansen, D. Di Giuseppe, JK. Wallman, K. Pavelka, J. Závada, C. Codreanu, B. Glintborg, AG. Loft, H. Santos, MH. Lourenço, MJ. Nissen, A. Ciurea, L. Kuusalo, V. Rantalaiho, B. Michelsen, P. Mielnik, KP. Pirkmajer, Z. Rotar, B. Gudbjornsson, O. Palsson, I. van der Horst-Bruinsma, M. van de Sande, I. Castrejón, GJ. Macfarlane, K. Laas, M. Østergaard, LM. Ørnbjerg
- 520 9_
- $a OBJECTIVE: In patients with axial spondyloarthritis (axSpA) initiating secukinumab (SEC), we aimed to identify baseline (treatment start) predictors of achieving low disease activity (LDA) after 6 months, as measured by the Axial Spondyloarthritis Disease Activity Score using C-reactive protein (ASDAS-CRP) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), as well as treatment continuation after 12 months. METHODS: From 11 European registries, patients with axSpA who initiated SEC treatment in routine care, with available data on 6-month ASDAS-CRP and BASDAI assessments were included. Logistic regression analyses on multiply imputed baseline data were performed; potential baseline predictors included demographic, diagnosis, lifestyle, clinical, and patient-reported variables. RESULTS: In a pooled cohort of 1174 patients with axSpA, 5 of 19 potential assessed variables were mutually predictive for achieving LDA by ASDAS-CRP and BASDAI: higher physician global assessment score, noncurrent smoking, lack of prior exposure to biologic/targeted synthetic disease-modifying antirheumatic drugs, and lower Health Assessment Questionnaire scores and BASDAI scores. Moreover, radiographic axSpA and CRP ≤ 10 mg/L were associated with achieving ASDAS-CRP LDA, and HLA-B27 positivity and history of psoriasis with achieving BASDAI LDA, whereas earlier time of secukinumab initiation (2015-2017) was associated with treatment continuation. CONCLUSION: In this European real-world study of patients with axSpA initiating SEC, predictors of achieving LDA by ASDAS-CRP and BASDAI at 6 months and remaining on treatment at 12 months included both clinical, patient-reported, and lifestyle factors, underscoring the complex mechanisms of real-world drug effectiveness.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a humanizované monoklonální protilátky $x terapeutické užití $7 D061067
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a axiální spondyloartritida $x farmakoterapie $7 D000089183
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a výsledek terapie $7 D016896
- 650 12
- $a antirevmatika $x terapeutické užití $7 D018501
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a stupeň závažnosti nemoci $7 D012720
- 650 _2
- $a registrace $7 D012042
- 650 _2
- $a C-reaktivní protein $x metabolismus $7 D002097
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Georgiadis, Stylianos $u M. Pons, MD, S. Georgiadis, PhD, S. Rasmussen, PhD, S.N. Christiansen, PhD, L.M. Ørnbjerg, MD, PhD, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark $1 https://orcid.org/0000000334859457
- 700 1_
- $a Hetland, Merete Lund $u M.L. Hetland, MD, PhD, DMSc, Z. Faizy Ahmadzay, MD, M. Østergaard, MD, PhD, DMSc, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
- 700 1_
- $a Ahmadzay, Zohra Faizy $u M.L. Hetland, MD, PhD, DMSc, Z. Faizy Ahmadzay, MD, M. Østergaard, MD, PhD, DMSc, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
- 700 1_
- $a Rasmussen, Simon $u M. Pons, MD, S. Georgiadis, PhD, S. Rasmussen, PhD, S.N. Christiansen, PhD, L.M. Ørnbjerg, MD, PhD, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark
- 700 1_
- $a Christiansen, Sara N $u M. Pons, MD, S. Georgiadis, PhD, S. Rasmussen, PhD, S.N. Christiansen, PhD, L.M. Ørnbjerg, MD, PhD, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark
- 700 1_
- $a Di Giuseppe, Daniela $u D. Di Giuseppe, PhD, Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
- 700 1_
- $a Wallman, Johan K $u J.K. Wallman, MD, PhD, Department of Clinical Sciences Lund, Rheumatology, Skåne University Hospital, Lund University, Lund, Sweden $1 https://orcid.org/0000000249152924
- 700 1_
- $a Pavelka, Karel $u K. Pavelka, MD, PhD, J. Závada, MD, PhD, Institute of Rheumatology, and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Závada, Jakub $u K. Pavelka, MD, PhD, J. Závada, MD, PhD, Institute of Rheumatology, and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Codreanu, Catalin $u C. Codreanu, PhD, Center for Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania
- 700 1_
- $a Glintborg, Bente $u B. Glintborg, MD, PhD, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Copenhagen, and DANBIO Registry, Rigshospitalet, Glostrup, Denmark $1 https://orcid.org/0000000289318482
- 700 1_
- $a Loft, Anne G $u A.G. Loft, MD, DMSc, Department of Rheumatology, Aarhus University Hospital, and Department of Clinical Medicine, Aarhus University, Aarhus, Denmark $1 https://orcid.org/000000016374841X
- 700 1_
- $a Santos, Helena $u H. Santos, MD, PhD, Instituto Português de Reumatologia, and Comprehensive Health Research Center (CHRC), Nova Medical School, Lisbon, Portugal $1 https://orcid.org/0000000313968988
- 700 1_
- $a Lourenço, Maria H $u M.H. Lourenço, PhD, Rheumatology Department, Centro Hospitalar de Lisboa Ocidental, and Comprehensive Health Research Center (CHRC), NOVA Medical School, Lisbon, Portugal
- 700 1_
- $a Nissen, Michael J $u M.J. Nissen, MD, PhD, Department of Rheumatology, Geneva University Hospital, Geneva, Switzerland
- 700 1_
- $a Ciurea, Adrian $u A. Ciurea, MD, PhD, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland $1 https://orcid.org/0000000278707132
- 700 1_
- $a Kuusalo, Laura $u L. Kuusalo, PhD, Centre for Rheumatology and Clinical Immunology, Turku University Hospital, and Department of Internal Medicine, University of Turku, Turku, Finland
- 700 1_
- $a Rantalaiho, Vappu $u V. Rantalaiho, PhD, Tampere University Hospital, Centre for Rheumatic Diseases, and Tampere University, Faculty of Medicine and Health Technology, Tampere, and Department of Internal Medicine, Kanta-Häme Central Hospital, Hämeenlinna, Finland
- 700 1_
- $a Michelsen, Brigitte $u B. Michelsen, PhD, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Glostrup, Denmark, and Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, and Research Unit, Sørlandet Hospital, Kristiansand, Norway $1 https://orcid.org/0000000301032840
- 700 1_
- $a Mielnik, Pawel $u P. Mielnik, MD, PhD, Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde, Førde, Norway
- 700 1_
- $a Pirkmajer, Katja P $u K.P. Pirkmajer, PhD, Z. Rotar, MD, PhD, Department of Rheumatology, University Medical Centre Ljubljana, and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
- 700 1_
- $a Rotar, Ziga $u K.P. Pirkmajer, PhD, Z. Rotar, MD, PhD, Department of Rheumatology, University Medical Centre Ljubljana, and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
- 700 1_
- $a Gudbjornsson, Bjorn $u B. Gudbjornsson, MD, PhD, Centre for Rheumatology Research, Landspitali University Hospital, and Faculty of Medicine, University of Iceland, Reykjavik, Iceland $1 https://orcid.org/0000000346316505
- 700 1_
- $a Palsson, Olafur $u O. Palsson, MD, Department of Clinical Sciences Lund, Rheumatology, Skåne University Hospital, Lund University, Lund, Sweden, and Faculty of Medicine, University of Iceland, Reykjavik, Iceland
- 700 1_
- $a van der Horst-Bruinsma, Irene $u I. van der Horst-Bruinsma, MD, PhD, Rheumatology, Radboud University Medical Center, Nijmegen, the Netherlands
- 700 1_
- $a van de Sande, Marleen $u M. van de Sande, MD, PhD, Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Institute for Infection & Immunity, and Amsterdam Rheumatology Immunology Center, Reade and Amsterdam UMC, Amsterdam, the Netherlands
- 700 1_
- $a Castrejón, Isabel $u I. Castrejón, MD, PhD, Department of Rheumatology, Hospital General Universitario Gregorio Marañón, and Faculty of Medicine, Complutense University of Madrid, Madrid, Spain
- 700 1_
- $a Macfarlane, Gary J $u G.J. Macfarlane, MD, PhD, Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, UK $1 https://orcid.org/0000000323223314
- 700 1_
- $a Laas, Karin $u K. Laas, PhD, Department of Rheumatology, East-Tallinn Central Hospital, Tallinn, Estonia
- 700 1_
- $a Østergaard, Mikkel $u M.L. Hetland, MD, PhD, DMSc, Z. Faizy Ahmadzay, MD, M. Østergaard, MD, PhD, DMSc, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark $1 https://orcid.org/000000033690467X
- 700 1_
- $a Ørnbjerg, Lykke M $u M. Pons, MD, S. Georgiadis, PhD, S. Rasmussen, PhD, S.N. Christiansen, PhD, L.M. Ørnbjerg, MD, PhD, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark $1 https://orcid.org/0000000278326831
- 773 0_
- $w MED00002935 $t Journal of rheumatology $x 1499-2752 $g Roč. 52, č. 6 (2025), s. 572-582
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39892891 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731091052 $b ABA008
- 999 __
- $a ok $b bmc $g 2366421 $s 1252688
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 52 $c 6 $d 572-582 $e 20250601 $i 1499-2752 $m Journal of rheumatology $n J Rheumatol $x MED00002935
- LZP __
- $a Pubmed-20250708
